查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1933898

RNAi療法市場按遞送技術、治療分子類型、研發階段、給藥途徑、製劑類型、適應症和最終用戶分類－全球預測，2026-2032年

RNAi Therapeutics Market by Delivery Technology, Therapeutic Molecule Type, Development Stage, Route Of Administration, Formulation Type, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 RNAi 療法市場在 2025 年的價值為 55.4 億美元，在 2026 年成長至 63.6 億美元，到 2032 年達到 152.3 億美元，複合年成長率為 15.53%。

主要市場統計數據
基準年 2025 55.4億美元
預計年份：2026年 63.6億美元
預測年份：2032年 152.3億美元
複合年成長率 (%) 15.53%

RNA干擾療法已從實驗室研究發展成為核酸醫學的核心支柱，這得益於精準基因靜默機制和臨床療效的顯著提升。其核心在於利用小干擾RNA（siRNA）及其相關構建體，透過細胞內訊號路徑沉默致病標靶基因，為過去難以治癒的疾病提供了一種新的治療途徑。化學、偶聯策略和遞送平台的進步，系統性地降低了脫靶效應，提高了耐受性，並使藥物在更廣泛的適應症範圍內展現出可預測的藥理作用。

因此，臨床計畫目前探索的疾病領域已不再局限於遺傳性代謝疾病，還包括複雜的腫瘤應用、傳染性病原體和心血管標靶。生產技術、分析表徵和監管政策的同步改進，降低了曾經限制轉化研究進展的技術不確定性。更重要的是，以病人為中心的考量，例如皮下給藥和延長療效持續時間，正在重塑研發重點和商業性化模式。

總體而言，RNAi療法的引入標誌著一種新的治療方法走向成熟，成為一個可行的治療領域。本執行摘要的其餘部分概述了相關人員在分配資源、建立夥伴關係和規劃臨床專案時應考慮的最重要的科學、營運和策略發展。

變革性轉變正在重新定義RNAi療法：從遞送創新到監管進展，再到跨學科合作，共同推動臨床成功

近年來，RNAi療法領域發生了一系列變革性變化，這些變化建立在遞送技術、化學和監管實踐的持續創新之上，從而重塑了該領域的格局。其中最顯著的是標靶化偶聯物和改良奈米顆粒系統的出現，它們能夠實現器官選擇性遞送，同時限制全身暴露。例如，將藥物標靶化肝細胞的GalNAc樣受體以及用於肝外分佈的特化脂質奈米顆粒製劑，都很好地體現了遞送技術的進步如何開闢了新的靶點類別和給藥模式。

評估2025年美國關稅措施對RNAi供應鏈、製造成本、臨床開發時間表和國際合作動態的累積影響

2025年美國關稅措施為RNAi的研發和生產帶來了新的營運複雜性，影響了組件成本、供應商選擇和跨境合作。對某些進口原料、特殊脂質和特定電子元件徵收的關稅導致採購成本增加，促使專案發起公司重新評估其供應商佈局。由於先進的遞送系統通常依賴國際採購的專有脂質、偶聯物和客製化API的組合，成本結構的轉變正迫使各公司實現採購多元化，並協商長期供應協議以確保專案按時完成。

從適應症、給藥平台、分子類型、研發階段、給藥途徑、製劑和最終用戶需求模式等方面進行關鍵細分洞察

詳細的細分分析揭示了科學機會與商業性需求在適應症、遞送技術、分子類型、研發階段、給藥途徑、製劑方法和最終用戶畫像等因素交匯之處。適應症細分涵蓋心血管疾病、感染疾病、代謝性疾病、腫瘤和罕見疾病。在腫瘤領域，研發人員的目標既包括骨髓惡性腫瘤，也固態腫瘤。其中，骨髓惡性腫瘤的研究進一步細分為白血病、淋巴瘤和骨髓瘤，而固態腫瘤的研究則著重於乳癌、肝癌和肺癌。如此廣泛的治療領域要求採用標靶遞送策略和生物標記主導的測試設計，以將各種療法的優勢與尚未滿足的需求相匹配。

影響RNAi技術應用的區域趨勢：對美洲、歐洲、中東和非洲以及亞太地區的研發、生產和市場進入的影響

全球RNAi生態系中存在區域差異，這些差異既帶來了機遇，也帶來了限制，美洲、歐洲、中東和非洲以及亞太地區呈現出截然不同的發展趨勢。在美洲，生物技術創新、創業投資和臨床試驗基礎設施的集中，有利於快速轉化應用和早期商業化。然而，高昂的研發成本和複雜的支付方環境，使得制定完善的市場進入計畫變得至關重要。在該地區，生技公司與大型製藥公司之間的合作十分常見，旨在加速後期研發和分銷策略。

企業策略、競爭定位和夥伴關係趨勢推動RNAi療法領域的創新和商業化路徑

在RNAi領域營運的公司正採取差異化的策略，以體現其技術優勢、規模擴張目標和夥伴關係策略。一些公司專注於平台卓越性，大力投資於遞送技術，旨在將藥物作用範圍擴展到肝臟以外，並提高腫瘤和中樞神經系統標靶的治療指數。另一些公司則強調臨床深度，將資源集中在有限的高價值適應症，並推動具有明確轉化途徑的後期研發專案。平台所有者與以治療為導向的申辦者之間的跨領域合作仍然很普遍，這種合作將遞送技術與特異性疾病的臨床專業知識相結合。

為產業領導者提供切實可行的建議，以加速臨床轉換、確保供應鏈的韌性、最佳化交付平台並降低商業化風險。

產業領導者應優先採取以下切實可行的措施，將科學潛力轉化為永續的臨床和商業性價值。首先，投資於多樣化的給藥方式，以降低單一平台風險。優先選擇在可生產性、組織特異性和監管清晰度方面取得平衡的技術。其次，透過建立多源採購、確保區域生產選項以及為關鍵脂質偶聯物檢測試劑建立策略性庫存緩衝，來增強供應鏈韌性。第三，在研發規劃早期階段就整合健康經濟學和真實世界證據框架，以支持報銷談判，並向支付方和醫療保健系統展示長期價值。

調查方法詳細介紹了用於綜合 RNAi 市場情報的多源證據收集、同行檢驗、分析框架和品管。

本研究綜合分析基於嚴謹的多面向方法，結合了專家面對面訪談和全面的證據綜合。關鍵見解源自於對研發高管、生產和供應鏈高管、臨床研究人員以及監管顧問的結構化訪談，旨在獲取關於技術成熟度和營運挑戰的實地觀點。此外，還系統性地回顧了同行評審文獻、會議報告、監管指導文件和公司資訊披露，以確保技術說明和戰略趨勢反映公開可獲得的證據。

總結RNAi療法中的技術進步、營運挑戰、策略重點和相關人員機遇

RNAi療法領域正處於轉折點，平台成熟度、遞送技術創新以及策略營運選擇將決定哪些項目能夠取得臨床和商業性成功。標靶化偶聯物、奈米顆粒工程和寡核苷酸化學的進步顯著拓展了RNAi療法的適應症範圍，而監管政策的明確化和生產過程的改進也消除了一些傳統的臨床應用障礙。同時，供應鏈風險、關稅帶來的成本壓力以及對強力的衛生經濟學證據的需求等營運挑戰，也要求申辦方制定深思熟慮的策略應對措施。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 RNAi療法市場：依遞送技術分類

  • 外泌體
  • GalNAc綴合物
  • 脂質奈米顆粒
  • 聚合物奈米粒子
  • 病毒載體

9. 依治療分子類型分類的RNAi療法市場

  • 微型RNA
  • 短髮夾RNA
  • 小干擾RNA

第10章 RNAi療法市場依研發階段分類

  • 商業的
  • 第一階段測試
  • 第二階段
  • 第三階段
  • 臨床前階段

第11章 RNAi療法市場依給藥途徑分類

  • 鼻腔給藥
  • 靜脈注射
  • 玻璃體內注射
  • 皮下注射

第12章：按製劑類型分類的RNAi療法市場

  • 液體配方
  • 冷凍乾燥製劑

第13章 RNAi療法市場（依適應症分類）

  • 心血管疾病
  • 感染疾病
  • 代謝性疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
      • 白血病
      • 淋巴瘤
      • 多發性骨髓瘤
    • 固態腫瘤
      • 乳癌
      • 肝癌
      • 肺癌
  • 罕見疾病

第14章 RNAi療法市場（以最終用戶分類）

  • 學術機構
  • 醫院
  • 研究所
  • 專科診所

第15章 RNAi療法市場：按地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：RNAi療法市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國RNAi療法市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國RNAi療法市場

第17章：中國的RNAi療法市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • Benitec Biopharma Limited
  • Dynacure SAS
  • Novartis AG
  • OliX Pharmaceuticals, Inc.
  • Ona Therapeutics SL
  • Phio Pharmaceuticals Corp.
  • Quark Pharmaceuticals, Inc.
  • Roche Holding AG
  • Silence Therapeutics plc
  • Simaomics, Inc.
Product Code: MRR-C36616F699B1

The RNAi Therapeutics Market was valued at USD 5.54 billion in 2025 and is projected to grow to USD 6.36 billion in 2026, with a CAGR of 15.53%, reaching USD 15.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.54 billion
Estimated Year [2026] USD 6.36 billion
Forecast Year [2032] USD 15.23 billion
CAGR (%) 15.53%

RNA interference therapeutics have transitioned from laboratory curiosity to a core pillar of nucleic acid medicine, driven by precise gene-silencing mechanisms and growing clinical validation. At their core, small interfering RNAs and related constructs harness endogenous cellular pathways to downregulate disease-driving targets, offering therapeutic approaches for conditions historically deemed intractable. Advances in chemistry, conjugation strategies, and delivery platforms have systematically reduced off-target activity and improved tolerability, enabling predictable pharmacology for a broader range of indications.

As a consequence, clinical programs now explore diverse disease spaces beyond inherited metabolic disorders, including complex oncology applications, infectious agents, and cardiovascular targets. Parallel improvements in manufacturing, analytical characterization, and regulatory clarity have reduced technical uncertainties that once constrained translational momentum. Importantly, patient-centric considerations such as subcutaneous administration and extended durability of effect are reshaping development priorities and commercial access models.

Taken together, the introduction of RNAi therapeutics represents a maturation of a novel modality into an actionable therapeutic class. The remainder of this executive summary synthesizes the most consequential scientific, operational, and strategic developments that stakeholders must weigh when allocating resources, forming partnerships, and planning clinical programs.

Transformative shifts redefining RNAi therapeutics from delivery breakthroughs to regulatory progress and cross-disciplinary convergence enabling clinical success

Recent years have produced a set of transformative shifts that now define the RNAi therapeutic landscape, rooted in persistent innovation across delivery, chemistry, and regulatory practice. The most visible change is the emergence of targeted conjugates and refined nanoparticle systems that enable organ-selective delivery with lower systemic exposure. GalNAc-style receptor targeting for hepatocytes and tailored lipid nanoparticle formulations for extrahepatic distribution exemplify how delivery advances have unlocked new target classes and dosing paradigms.

Complementing delivery progress, improvements in oligonucleotide design and stabilization chemistries have enhanced potency and durability, permitting less frequent dosing and more convenient routes of administration. This has significant implications for patient adherence and health system uptake. Moreover, the field is experiencing a cross-disciplinary convergence: insights from gene-editing, biologics manufacturing, and immuno-oncology are being integrated into RNAi program design, accelerating combination strategies and novel therapeutic concepts.

Regulatory agencies have matured in their approach to nucleic acid therapeutics, providing clearer expectations for nonclinical safety packages, bioanalytics, and comparability studies. As a result, sponsors are able to de-risk program development earlier, enabling more ambitious clinical hypotheses. Collectively, these shifts are reducing translational friction, broadening therapeutic applicability, and reframing commercial and clinical strategies across the ecosystem.

Assessing the cumulative impact of United States tariffs 2025 on RNAi supply chains, manufacturing costs, clinical timelines, and global collaboration dynamics

United States tariff policies implemented in 2025 have introduced a new layer of operational complexity for RNAi development and manufacturing, influencing component costs, supplier selection, and cross-border collaboration. Tariffs on certain imported raw materials, specialized lipids, and select electronic equipment have translated into increased procurement costs and prompted sponsors to reassess supplier footprints. Because advanced delivery systems often rely on a mix of proprietary lipids, conjugates, and custom APIs sourced internationally, shifting cost structures have encouraged firms to diversify sourcing and negotiate longer-term supply agreements to preserve program timelines.

In parallel, clinical operations have been affected through altered logistics economics for cold-chain shipments and lab consumables. Sponsors undertaking global trials have experienced the need to reallocate budget and adjust site selection criteria where import-related costs are material. These constraints have not only prompted operational adaptations but have accelerated conversations about regional manufacturing capacity and on-shoring of critical components to reduce exposure to tariff volatility and transit disruptions.

Strategically, the tariff environment has increased the value of vertical integration and partnership models that secure upstream inputs. It has also encouraged procurement teams to pursue design-for-supply strategies that reduce dependence on tariff-vulnerable inputs, such as selecting alternative excipients or platform components with more geographically diversified supply chains. In sum, the cumulative impact of tariff shifts is reshaping procurement, manufacturing planning, and clinical logistics in ways that favor resilient, diversified operational models.

Key segmentation insights across indications, delivery platforms, molecule types, development stages, administration routes, formulations, and end-user demand patterns

A nuanced segmentation lens reveals where scientific opportunity and commercial demand intersect across indications, delivery technologies, molecule types, development stages, routes of administration, formulation approaches, and end-user profiles. Indication segmentation spans cardiovascular disorders, infectious diseases, metabolic disorders, oncology, and rare diseases; within oncology, developers pursue both hematological malignancies and solid tumors, with hematological workstreams further subdivided into leukemia, lymphoma, and myeloma while solid tumor efforts concentrate on breast, liver, and lung cancer. This therapeutic breadth calls for targeted delivery strategies and biomarker-driven trial designs that match modality strengths to unmet clinical needs.

Delivery technology segmentation covers exosomes, GalNAc conjugates, lipid nanoparticles, polymeric nanoparticles, and viral vectors, each offering different tissue tropisms, manufacturing challenges, and regulatory pathways. Therapeutic molecule types include microRNA constructs, short hairpin RNA, and small interfering RNA, which diverge in mechanism nuance and intracellular processing requirements. Development stage segmentation ranges from commercial to Phase I, Phase II, Phase III, and preclinical programs, reflecting a pipeline spectrum that demands tailored regulatory and manufacturing strategies at each milestone.

Route-of-administration segmentation encompasses intranasal, intravenous, intravitreal, and subcutaneous approaches, with implications for patient experience, clinical setting, and device integration. Formulation type segmentation distinguishes between liquid and lyophilized presentations, affecting stability profiles and logistics. Finally, end-user segmentation includes academic institutions, hospitals, research laboratories, and specialty clinics, highlighting the diverse stakeholder base that shapes adoption dynamics and clinical trial site readiness. Together, these segmentation axes guide prioritization of R&D investments and operational design, underscoring the need for adaptable platforms and targeted commercialization models.

Regional dynamics shaping RNAi adoption across the Americas, Europe Middle East & Africa, and Asia-Pacific with implications for R&D, manufacturing, and market access

Regional variation drives both opportunity and constraint across the global RNAi ecosystem, with distinct dynamics observable in the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, concentration of biotech innovation, venture capital, and clinical trial infrastructure supports rapid translational activity and early commercialization, though high development costs and complex payor landscapes require sophisticated market access planning. Collaboration between biotechs and large pharmaceutical partners often accelerates late-stage development and distribution strategies within this region.

Across Europe Middle East & Africa, regulatory harmonization and well-established public healthcare systems shape evidence expectations and reimbursement pathways, prompting sponsors to prioritize robust health economics data and real-world evidence strategies. Regional manufacturing capabilities and strong scientific hubs offer opportunities for localized production and clinical partnerships, particularly when market access proofs are required for public payors. In the Asia-Pacific region, a combination of large patient populations, expanding clinical research capacity, and growing manufacturing capabilities creates a compelling environment for scaling late-stage programs and cost-effective production. Regulatory authorities in this region have increasingly adopted pragmatic frameworks for nucleic acid therapeutics, which can shorten timelines for local development and registration when aligned with global dossiers.

Taken together, these regional distinctions inform where to site clinical programs, how to structure supply chains, and which evidence strategies will most effectively support adoption and reimbursement across diverse healthcare systems.

Company strategies, competitive positioning, and partnership trends driving innovation and commercialization pathways in the RNAi therapeutics landscape

Companies operating in the RNAi space are pursuing differentiated strategies that reflect their technological core, scale ambitions, and partnership approaches. Some organizations focus on platform excellence, investing heavily in delivery technologies designed to expand tissue reach beyond the liver and to improve therapeutic indices for oncology and central nervous system targets. Others emphasize clinical depth by concentrating resources on a narrow set of high-value indications and advancing late-stage assets with clear translational pathways. Cross-sector collaborations between platform owners and therapeutic-focused sponsors remain prevalent, combining delivery know-how with disease-specific clinical expertise.

Strategic M&A and licensing activity continues to be a lever for rapid capability acquisition, enabling firms to integrate proprietary chemistries or manufacturing know-how without building in-house capabilities from scratch. Manufacturing partnerships and capacity agreements are also a core element of corporate strategy, as firms seek to secure reliable supply and predictable timelines. From an organizational perspective, successful companies typically align clinical, CMC, and regulatory functions early to ensure comparability and analytics scale with program advancement. Finally, companies that invest in payer engagement and health economics evidence generation earlier in development tend to face fewer barriers at launch, particularly for treatments addressing chronic conditions or large patient populations.

Actionable recommendations for industry leaders to accelerate clinical translation, secure resilient supply chains, optimize delivery platforms, and de-risk commercialization

Industry leaders should prioritize a set of actionable moves to translate scientific promise into sustainable clinical and commercial value. First, invest in delivery diversification to mitigate single-platform risk; prioritize technologies that offer a balance of manufacturability, tissue specificity, and regulatory clarity. Second, strengthen supply chain resilience by establishing multi-source procurement, regional manufacturing options, and strategic inventory buffers for critical lipids, conjugates, and analytical reagents. Third, integrate health economics and real-world evidence frameworks into development plans early to support reimbursement discussions and to demonstrate long-term value to payors and health systems.

Fourth, foster strategic partnerships that pair delivery platform owners with disease-focused clinical teams, thereby accelerating molecule advancement while sharing development risk. Fifth, design clinical programs with patient-centric administration routes and dosing intervals that improve adherence and broaden potential settings of care. Sixth, prioritize regulatory engagement through early scientific advice and iterative dialogue on nonclinical package composition and comparability strategies. Finally, build cross-functional decision forums that align R&D, manufacturing, regulatory, and commercial stakeholders to accelerate go/no-go decisions and ensure readiness for scale-up once clinical validation milestones are achieved.

Research methodology detailing multi-source evidence gathering, expert validation, analytical frameworks, and quality controls used to synthesize RNAi market intelligence

This research synthesis is grounded in a rigorous, multi-method approach that combined primary expert engagement with comprehensive evidence synthesis. Primary insights were derived from structured interviews with senior R&D leaders, manufacturing and supply chain executives, clinical investigators, and regulatory advisors to capture frontline perspectives on technological maturation and operational challenges. These conversations were supplemented by systematic review of peer-reviewed literature, conference proceedings, regulatory guidance documents, and company disclosures to ensure that technical descriptions and strategic trends reflect publicly available evidence.

Analytical frameworks included cross-sectional segmentation mapping, scenario-based impact analysis for supply chain and tariff dynamics, and qualitative triangulation to reconcile differing expert viewpoints. Quality control processes entailed reproducibility checks, source triangulation for key assertions, and validation of technical terminology with subject-matter experts. Where necessary, discrepancies were resolved through follow-up consultations to ensure clarity and factual alignment. The methodology emphasizes transparency in evidence sources and interpretive steps, enabling readers to understand how strategic conclusions were reached and where ongoing data collection may be most valuable.

Conclusion synthesizing technological advances, operational challenges, strategic priorities, and opportunities for stakeholders in RNAi therapeutics

The RNAi therapeutics landscape is at an inflection point where platform maturity, delivery innovation, and strategic operational choices determine which programs will achieve clinical and commercial impact. Advances in targeted conjugates, nanoparticle engineering, and oligonucleotide chemistries have materially broadened feasible indications, while regulatory clarity and improved manufacturing practices have reduced several historical barriers to translation. At the same time, operational challenges such as supply chain exposure, tariff-induced cost pressures, and the need for robust health economics evidence require deliberate strategic responses from sponsors.

Ultimately, organizations that align technological capability with resilient operational design and payer-aware development strategies will be best positioned to convert scientific promise into patient benefit and sustainable business outcomes. The synthesis and recommendations presented here are intended to inform executive decision-making across R&D, manufacturing, and commercial functions, enabling stakeholders to prioritize investments, forge productive partnerships, and accelerate the responsible delivery of RNAi therapeutics to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNAi Therapeutics Market, by Delivery Technology

  • 8.1. Exosomes
  • 8.2. GalNAc Conjugates
  • 8.3. Lipid Nanoparticles
  • 8.4. Polymeric Nanoparticles
  • 8.5. Viral Vectors

9. RNAi Therapeutics Market, by Therapeutic Molecule Type

  • 9.1. Microrna
  • 9.2. Short Hairpin Rna
  • 9.3. Small Interfering Rna

10. RNAi Therapeutics Market, by Development Stage

  • 10.1. Commercial
  • 10.2. Phase I
  • 10.3. Phase Ii
  • 10.4. Phase Iii
  • 10.5. Preclinical

11. RNAi Therapeutics Market, by Route Of Administration

  • 11.1. Intranasal
  • 11.2. Intravenous
  • 11.3. Intravitreal
  • 11.4. Subcutaneous

12. RNAi Therapeutics Market, by Formulation Type

  • 12.1. Liquid Formulation
  • 12.2. Lyophilized Formulation

13. RNAi Therapeutics Market, by Indication

  • 13.1. Cardiovascular Disorders
  • 13.2. Infectious Diseases
  • 13.3. Metabolic Disorders
  • 13.4. Oncology
    • 13.4.1. Hematological Malignancies
      • 13.4.1.1. Leukemia
      • 13.4.1.2. Lymphoma
      • 13.4.1.3. Myeloma
    • 13.4.2. Solid Tumors
      • 13.4.2.1. Breast Cancer
      • 13.4.2.2. Liver Cancer
      • 13.4.2.3. Lung Cancer
  • 13.5. Rare Diseases

14. RNAi Therapeutics Market, by End User

  • 14.1. Academic Institutions
  • 14.2. Hospitals
  • 14.3. Research Laboratories
  • 14.4. Specialty Clinics

15. RNAi Therapeutics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. RNAi Therapeutics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. RNAi Therapeutics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States RNAi Therapeutics Market

19. China RNAi Therapeutics Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Alnylam Pharmaceuticals, Inc.
  • 20.6. Arbutus Biopharma Corporation
  • 20.7. Arbutus Biopharma Corporation
  • 20.8. Arrowhead Pharmaceuticals, Inc.
  • 20.9. Benitec Biopharma Limited
  • 20.10. Dynacure SAS
  • 20.11. Novartis AG
  • 20.12. OliX Pharmaceuticals, Inc.
  • 20.13. Ona Therapeutics SL
  • 20.14. Phio Pharmaceuticals Corp.
  • 20.15. Quark Pharmaceuticals, Inc.
  • 20.16. Roche Holding AG
  • 20.17. Silence Therapeutics plc
  • 20.18. Simaomics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GALNAC CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GALNAC CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GALNAC CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MICRORNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MICRORNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MICRORNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SHORT HAIRPIN RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SHORT HAIRPIN RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SHORT HAIRPIN RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVITREAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVITREAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INTRAVITREAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIQUID FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIQUID FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYOPHILIZED FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYOPHILIZED FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYOPHILIZED FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GCC RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. GCC RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. GCC RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. GCC RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 230. GCC RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. G7 RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 258. G7 RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. G7 RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 261. G7 RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. G7 RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 263. G7 RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. NATO RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. NATO RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. NATO RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. NATO RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. NATO RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 274. NATO RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 275. NATO RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA RNAI THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA RNAI THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA RNAI THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA RNAI THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA RNAI THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA RNAI THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)